Clinical trial readout dates for Trevi Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is August 2027.
| Phase 3 NAL ER Idiopathic Pulmonary Fibrosis · NCT07868419 | August 2027 Recruiting |
| Phase 2 NAL ER Refractory Chronic Cough · NCT07671924 | September 2027 Recruiting |
| Phase 3 NAL ER Idiopathic Pulmonary Fibrosis · NCT07671911 | June 2028 Recruiting |
Trevi Therapeutics Inc. reported $299M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $21M; at that rate the cash would last about 14 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |